PriceTargets.com logo

First Tracks Biotherapeutics - TRAX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $71.33
  • Forecasted Upside: 63.53%
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$43.62 As of 10/26/2026 12:26 PM ET
▼ -0.43 (-0.98%)

This chart shows the closing price for TRAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New First Tracks Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TRAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TRAX

Analyst Price Target is $71.33
▲ +63.53% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for First Tracks Biotherapeutics in the last 3 months. The average price target is $71.33, with a high forecast of $100.00 and a low forecast of $31.00. The average price target represents a 63.53% upside from the last price of $43.62.

This chart shows the closing price for TRAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in First Tracks Biotherapeutics. This rating has held steady since June 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2026
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/26/2026
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/26/2026

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/16/2026Leerink PartnersBoost TargetOutperform ➝ Outperform$70.00 ➝ $90.00
10/13/2026EvercoreReiterated RatingOutperform ➝ Outperform$70.00
10/13/2026Canaccord Genuity GroupBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
10/12/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$62.00 ➝ $70.00
10/9/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$62.00
10/8/2026Weiss RatingsUpgradeSell (D) ➝ Sell (D+)
9/30/2026Canaccord Genuity GroupInitiated CoverageBuy$50.00
9/18/2026EvercoreInitiated CoverageOutperform$65.00
9/18/2026EvercoreInitiated CoverageOutperform$65.00
9/16/2026GuggenheimInitiated CoverageBuy$100.00
9/16/2026UBS GroupInitiated CoverageBuy ➝ Buy
9/16/2026GuggenheimInitiated CoverageBuy$100.00
9/16/2026GuggenheimInitiated CoverageBuy$100.00
9/3/2026HC WainwrightReiterated RatingBuy ➝ Buy$57.00
8/18/2026Wolfe ResearchInitiated CoverageOutperform$83.00
8/13/2026Weiss RatingsInitiated CoverageSell (D)
8/13/2026Piper SandlerBoost TargetOverweight ➝ Overweight$54.00 ➝ $95.00
8/13/2026HC WainwrightBoost TargetBuy ➝ Buy$44.00 ➝ $57.00
8/13/2026BarclaysBoost TargetOverweight ➝ Overweight$48.00 ➝ $65.00
8/13/2026WedbushBoost TargetOutperform ➝ Outperform$60.00 ➝ $70.00
8/10/2026UBS GroupBoost TargetBuy ➝ Buy$45.00 ➝ $65.00
7/28/2026Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$30.00 ➝ $55.00
7/28/2026WedbushBoost TargetOutperform ➝ Outperform$30.00 ➝ $60.00
7/21/2026BarclaysBoost TargetOverweight ➝ Overweight$40.00 ➝ $48.00
7/10/2026HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $44.00
7/8/2026HC WainwrightReiterated RatingBuy ➝ Buy$30.00
6/8/2026Wells Fargo & CompanyInitiated CoverageOverweight$30.00
6/8/2026Wells Fargo & CompanyInitiated CoverageOverweight$30.00
5/4/2026Piper SandlerInitiated CoverageOverweight$54.00
4/28/2026HC WainwrightInitiated CoverageBuy$30.00
4/28/2026HC WainwrightUpgradeStrong-Buy$30.00
4/27/2026Zacks ResearchUpgradeHold
4/24/2026WedbushInitiated CoverageOutperform$30.00
4/24/2026Leerink PartnersInitiated CoverageOutperform$46.00
4/23/2026JPMorgan Chase & Co.Initiated CoverageOverweight$31.00
4/22/2026BarclaysInitiated CoverageOverweight$40.00
4/21/2026UBS GroupInitiated CoverageBuy$45.00
(Data available from 10/26/2021 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2026
  • 0 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/27/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2026
  • 13 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/26/2026

Current Sentiment

  • 13 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.
Read More

Today's Range

Now: $43.62
Low: $41.83
High: $45.42

50 Day Range

MA: $38.73
Low: $30.59
High: $45.50

52 Week Range

Now: $43.62
Low: $14.72
High: $49.91

Volume

180,811 shs

Average Volume

728,077 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of First Tracks Biotherapeutics?

The following sell-side analysts have issued stock ratings on First Tracks Biotherapeutics in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Evercore Inc, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Piper Sandler, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, Wolfe Research, and Zacks Research.
View the latest analyst ratings for TRAX.

What is the current price target for First Tracks Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for First Tracks Biotherapeutics in the last year. Their average twelve-month price target is $71.33, suggesting a possible upside of 61.9%. Guggenheim has the highest price target set, predicting TRAX will reach $100.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $31.00 for First Tracks Biotherapeutics in the next year.
View the latest price targets for TRAX.

What is the current consensus analyst rating for First Tracks Biotherapeutics?

First Tracks Biotherapeutics currently has 1 sell rating, 1 hold rating and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TRAX.

What other companies compete with First Tracks Biotherapeutics?

Other companies that are similar to First Tracks Biotherapeutics include Rhythm Pharmaceuticals, Ligand Pharmaceuticals, Kiniksa Pharmaceuticals International, GRAIL and Immunovant. Learn More about companies similar to First Tracks Biotherapeutics.

How do I contact First Tracks Biotherapeutics' investor relations team?

First Tracks Biotherapeutics' physical mailing address is 10770 Wateridge Circle, Suite 210, San Diego, CA, 92121. The company's listed phone number is 858-362-6295 and its investor relations email address is [email protected]. The official website for First Tracks Biotherapeutics is www.firsttracksbio.com. Learn More about contacing First Tracks Biotherapeutics investor relations.